Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leader in genome editing, will announce its first quarter 2023 financial results and operational highlights on May 4, 2023, at 8 a.m. ET. Investors can participate via a conference call or a live webcast. The company focuses on developing potentially curative therapeutics using CRISPR-based technologies through its in vivo and ex vivo programs, targeting specific disease-causing genes. Intellia aims to harness the full potential of genome editing for transformative genetic therapies, supported by its robust intellectual property portfolio and clinical development experience.

Intellia Therapeutics (NASDAQ:NTLA) announced the appointment of Bill Chase to its board of directors, effective immediately. Chase will also chair the audit committee, succeeding Caroline Dorsa, who is retiring on June 15, 2023, following her appointment as chair of Biogen's board. Bill Chase has over 30 years of experience in financial management, having served as CFO at AbbVie and held various roles at Abbott. This leadership change is aimed at strengthening Intellia's governance as it advances its CRISPR-based therapies into late-stage clinical development. CEO John Leonard emphasized Chase's financial acumen as a valuable asset in the company's mission to develop novel gene therapies.

Intellia Therapeutics (NASDAQ: NTLA) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational therapy NTLA-2002, aimed at treating hereditary angioedema (HAE). This CRISPR-based treatment targets the kallikrein B1 (KLKB1) gene to prevent life-threatening swelling attacks. The RMAT designation facilitates accelerated development and review, including early FDA interactions and potential priority review. NTLA-2002 has also received Orphan Drug Designation and Innovation Passport status. Intellia is currently conducting a Phase 1/2 study to evaluate the safety and efficacy of NTLA-2002.

Intellia Therapeutics (NASDAQ: NTLA) announced that the FDA has cleared its IND application for NTLA-2002, a genome editing candidate aimed at treating hereditary angioedema (HAE). This approval allows the inclusion of the United States in the ongoing Phase 1/2 clinical trial. NTLA-2002 employs CRISPR technology to permanently inactivate the kallikrein B1 (KLKB1) gene, significantly reducing the frequency of HAE attacks. Intellia will rapidly begin patient enrollment for Phase 2 and anticipates data release from the Phase 1 study later this year. The company aims to revolutionize HAE treatment and has reported promising interim results from early trials.

Intellia Therapeutics (NTLA) announced key milestones in early 2023, including the initiation of a global Phase 2 study for NTLA-2002, a CRISPR-based treatment for hereditary angioedema. The IND application for NTLA-2002 has been submitted to enable patient enrollment in the U.S. Furthermore, the company plans to file an IND application for NTLA-2001 for ATTR amyloidosis by mid-2023, with a global pivotal trial expected by year-end. Intellia ended 2022 with $1.3 billion in cash. Major R&D expenses rose to $100 million, contributing to a net loss of $113.4 million for Q4 2022. Upcoming clinical data presentations in 2023 will support these developments.

Intellia Therapeutics (NASDAQ:NTLA) will announce its fourth quarter and full-year 2022 financial results on February 23, 2023, at 8 a.m. ET. Investors can join the conference call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international) five minutes prior. A live webcast will also be available through their website. Intellia is a leader in developing CRISPR-based genome editing therapeutics, focusing on innovative treatments for various diseases through in vivo and ex vivo programs. The company aims to unlock the full potential of genetic medicine.

Intellia Therapeutics (NASDAQ:NTLA) has received the Innovation Passport from the U.K. Medicines and Healthcare products Regulatory Agency for NTLA-2002, a genome editing therapeutic candidate aimed at treating hereditary angioedema (HAE). This designation allows entry into the Innovative Licensing and Access Pathway (ILAP), facilitating faster market access for innovative medicines. The Phase 2 portion of NTLA-2002's clinical study is expected to start in the first half of 2023, following ongoing Phase 1/2 trials focusing on the drug's safety and effectiveness.

Intellia Therapeutics (NASDAQ: NTLA) outlines its strategic priorities for 2023-2024, emphasizing late-stage development of CRISPR-based therapies NTLA-2001 and NTLA-2002. Key milestones include submitting IND applications for these treatments and initiating pivotal global studies by the end of 2023. The company ended 2022 with approximately $1.3 billion in cash, indicating a strong financial position. Intellia aims to advance novel gene editing technologies and maintain its leadership in genome editing through high-impact opportunities.

Intellia Therapeutics (NASDAQ:NTLA) has priced a public offering of 6,550,219 shares at $45.80 each, aiming to raise approximately $300 million. The underwriter, Goldman Sachs, has a 30-day option for an additional 982,532 shares. The offering is set to close around December 2, 2022, based on standard conditions. The shares are offered under an existing SEC registration statement. Intellia specializes in CRISPR-based genome editing therapies, focusing on potential cures for diseases through innovative therapeutic approaches.